
Torudokimab
Zura Bio holds an exclusive license for the development and commercialization of Torudokimab
IL33 is a validated drug target in both chronic obstructive pulmonary disease (COPD) and asthma.
Drug well tolerated in Phase 1 and 2 trials conducted by Lilly and shows utility in diseases driven by epithelial inflammation.
IL33 pathway
Targeting IL33 In Epithelial Driven Diseases

REFERENCES
IL33: Roles in Allergic Inflammation and Therapeutic Perspectives
Chan BCL, Lam CWK, Tam L-S and Wong CK (2019) Front. Immunol. 10:364.
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation
Cohen, E., Scott, I., Majithiya, J. et al. Nat Commun 6, 8327 (2015).
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H. N Engl J Med. 2021 Oct 28;385(18):1656-1668.